

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Benedetto, Umberto; Altman, Douglas G; Flather, Marcus; Gerry, Stephen; Gray, Alastair; Lees, Belinda; Taggart, David P; Arterial Revascularization Trial Investigators; (2018) Incidence and clinical implications of intraoperative bilateral internal thoracic artery graft conversion: Insights from the Arterial Revascularization Trial. The Journal of thoracic and cardiovascular surgery, 155 (6). 2346-2355.e6. ISSN 0022-5223 DOI: <https://doi.org/10.1016/j.jtcvs.2018.02.012>

Downloaded from: <http://researchonline.lshtm.ac.uk/id/eprint/4655233/>

DOI: <https://doi.org/10.1016/j.jtcvs.2018.02.012>

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

Incidence and clinical implications of intraoperative BITA grafts conversion. Insights from the Arterial Revascularization Trial.

Umberto Benedetto¹ MD PhD, Douglas G Altman² DSc, Marcus Flather³ MD, Stephen Gerry² MSc, Alastair Gray⁴ PhD, Belinda Lees¹ BSc PhD, David P Taggart⁵ MD PhD; on behalf of the ART investigators

¹Bristol Heart Institute, University of Bristol, School of Clinical Sciences, United Kingdom;

²Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, UK;

³Norwich Medical School, University of East Anglia and Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK

⁴Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK;

⁵Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK

Word count: 2372

Umberto Benedetto umberto.benedetto@bristol.ac.uk

Doug Altman doug.altman@csm.ox.ac.uk

Marcus Flather m.flather@uea.ac.uk

Stephen Gerry stephen.gerry@csm.ox.ac.uk

Alastair Gray alastair.gray@dph.ox.ac.uk

Belinda Lees belinda.lees@nds.ox.ac.uk

Taggart P David David.Taggart@ouh.nhs.uk

Declaration of interests: None for all authors

Role of the funding source: Supported by grants from the British Heart Foundation (SP/03/001), the U.K. Medical Research Council (G0200390), and the National Institute of Health Research Efficacy and Mechanism Evaluation Programme (09/800/29)

Corresponding Author

Umberto Benedetto MD PhD
Bristol Heart Institute, University of Bristol
Senate House,
Tyndall Avenue,
Bristol, BS8 1TH, UK
Tel: +44 (0)117 928 9000
Email: Umberto.benedetto@bristol.ac.uk

37 **ABBREVIATIONS**

- 38 ART: Arterial revascularization trial
- 39 BITA: Bilateral internal thoracic arteries
- 40 BMI: Body mass index
- 41 CABG: coronary artery bypass grafting
- 42 CVA: cerebrovascular accident
- 43 COPD: chronic obstructive pulmonary disease
- 44 ITA: internal thoracic artery
- 45 LVEF: left ventricular ejection fraction
- 46 MACCE: major cardiac and cerebrovascular events
- 47 MI: myocardial infarction
- 48 PCI: percutaneous coronary intervention
- 49 POAF: postoperative atrial fibrillation
- 50 PS: propensity score
- 51 SITA: Single internal thoracic artery
- 52 SVG: saphenous vein grafts
- 53 SMD: standardized mean difference

Central Message: The incidence of intraoperative bilateral internal thoracic artery (BITA) graft conversion in the ART was not irrelevant despite participating surgeons were requested to have expertise in BITA grafts.

Prospective statement: Reasons beyond bilateral internal thoracic artery (BITA) grafts underutilization remain unclear. In the ART participating surgeons were requested to have expertise in BITA grafts. We found that in the ART the incidence of intraoperative BITA graft conversion was not irrelevant thus supporting that BITA grafts may represent a challenge also for experienced surgeons.

Abstract

Background: The arterial revascularization trial (ART) has been designed to answer the question whether the use of bilateral internal thoracic arteries (BITA) can improve 10-year outcomes when compared to single internal thoracic artery (SITA). In the ART, a significant proportion of patients initially allocated to BITA received other conduit strategies. We sought to investigate the incidence and clinical implication of BITA grafts conversion in the ART.

Methods: Among patients enrolled in the ART (n=3102), we excluded those allocated to SITA (n=1554), those who did not undergo surgery (n=16) and those operated on but withdrew after randomization (n=7). Propensity score matching was used to compare converted vs non-converted BITA groups.

Results: A total of 1525 patients were operated with intention to receive BITA grafting. Of those, 233 (15.3%) were converted to other conduit selection strategies. Incidence of conversion largely varied across 28 centres involved (from 0% to 42.9%). The most common reason for BITA grafts conversion was the evidence of at least one internal thoracic artery not suitable which was reported in 77 cases. Patients with intraoperative BITA graft conversion received a lower number of grafts (2.95 ± 0.84 vs 3.21 ± 0.74 ; $P < 0.001$). However, hospital mortality rate was comparable to those who did not require BITA graft conversion (0 vs 1.6%; $P = 0.1$) as well as the incidence of major complications. At 5 years we found a non-significant excess of deaths (11.9% vs 8.4%; $P = 0.1$) and major adverse events (17.1% vs 13.2%; $P = 0.1$) mainly driven by an excess of revascularization in patients requiring conversion.

Conclusions: The incidence of intraoperative BITA graft conversion is not irrelevant. BITA graft conversion is not associated with increased operative morbidity but its effect on late outcomes remain uncertain.

Keywords: bilateral internal thoracic artery; randomised controlled trial; outcomes

Despite evidence from large observational studies have consistently suggested that the use of bilateral internal thoracic artery (BITA) graft improves long term survival when compared to single internal thoracic artery (SITA) graft in coronary artery bypass graft (CABG) surgery [1,2], the use of BITA graft remains particularly low. As a matter of fact, BITA grafting represents only 4–12% of all CABG procedures over the more traditional use of the SITA with additional saphenous vein grafts (SVG) [3]. Reasons for BITA underutilization are multifactorial. Most of surgeons just do not perform BITA grafting based on the increased risk of sternal wound complications and technical complexity [4,5]. However, same patients initially intended to receive BITA grafts requires intraoperative conversion to other conduits strategies. Incidence and causes of intraoperative BITA grafts conversion and its clinical implication has never been investigated.

The arterial revascularization trial (ART) has been designed to answer the question whether the use of bilateral internal thoracic arteries (BITA) can improve 10-year outcomes when compared to single internal thoracic artery (SITA) in coronary artery bypass grafting (CABG) [6]. Interim 5-year results have shown similar clinical outcomes between the two groups [7]. In ART only surgeons with experience of ≥ 50 BITA operations were able to undertake BITA procedures in the trial [6]. We sought to investigate reasons for intraoperative BITA grafts conversion and its clinical implication by performing a post-hoc analysis of the ART.

Methods

A post-hoc analysis of 5-year outcomes of the ART trial was conducted. This research adheres to the principles set forth in the Declaration of Helsinki (<http://www.wma.net/en/30publications/10policies/b3/index.html>). Among patients enrolled in the ART (n=3102) from 2004 to 2007, we excluded those allocated to SITA (n=1554) and those who did not undergo surgery (n=16) and those operated on but withdrew after randomization (n=7).

Trial design

The ART was approved by the institutional review board of all participating centers, and informed consent was obtained from each participant. The protocol for the ART has been published [6]. Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 hospitals in 7 countries, with patients being randomized equally to SITA or BITA grafts. Eligible patients were those with multivessel coronary artery disease undergoing CABG. BITA grafts configuration (y graft vs. in-situ graft vs. free graft) was left at discretion of the surgeon (video). Patients requiring single grafts or redo CABG were excluded. Patients with evolving MI (defined as the rise and fall of a biomarker together with one of a longer list of criteria comprising ischaemic symptoms, the development of pathologic Q waves, ischaemic ECG changes, and a coronary artery intervention) were also excluded. However, patients with unstable angina defined as pain on any activity or rest pain were included.

Follow-up

Questionnaires were sent to study participants by post every year after surgery. No clinic visits were planned apart from the routine clinical 6-week post-operative visit. Participants were sent stamped addressed envelopes to improve the return rates of postal questionnaires. Study co-ordinators contacted participants by telephone to alert them to the questionnaire's arrival and to ask them about medications, adverse events and health services resource use. Five-year follow-up was completed for all patients included in the present analysis.

Study outcomes

Hospital outcomes investigated were re-exploration for bleeding, intra-aortic balloon pump (IABP) insertion, myocardial infarction (MI), cerebrovascular accident (CVA), postoperative atrial fibrillation (POAF), sternal complications revascularization and hospital mortality. Late outcomes were 5-year all-cause mortality and cumulative incidence of major cardiac and

cerebrovascular events (MACCE) including cardiovascular (CV) death, CVA, MI and repeat revascularization.

Outcomes definitions

Death was classified into cardiovascular and non-cardiovascular, where possible, using autopsy reports and death certificates. Congestive heart failure, arrhythmia or myocardial infarction, pulmonary embolus and dissection were considered cardiovascular causes of death.

MI was diagnosed when two of the following three criteria were present: 1. Unequivocal ECG changes; 2. Elevation of cardiac enzyme(s) above twice the upper limit of normal or diagnostic troponin rises; 3. Chest pain typical for acute MI which lasted more than 20 minutes. CVA was defined as new neurological deficit evidenced by clinical signs of paresis, plegia or new cognitive dysfunction including any mental status alteration lasting more than 24 hours and/or evidence on CT or MRI scan of recent brain infarct (less than 6 months). Repeat revascularization was defined as coronary bypass surgery or percutaneous coronary intervention (PCI) performed after trial procedure. Sternal complications included sternal wound infection requiring antibiotics, VAC therapy, debridement or reconstruction.

Statistical analysis

Multiple imputation ($m=3$) was used to address missing data. Rubin's method [8] was used to combine results from each of the imputed data sets (Amelia R package). Due to lack of randomization with regards to BITA conversion, a propensity score (PS) was generated for each patient from a multivariable logistic regression model (C-statistics 0.64) based on pre-specified set of covariates (as listed in Table 1) with requiring conversion vs non-converted as a binary dependent variable [9]. Pairs of patients were derived using greedy 1:3 matching with a calliper of width of 0.2 standard deviation of the logit of the PS (nonrandom R package). The quality of the match was assessed by comparing selected pre-treatment variables in propensity

score-matched patients using the standardized mean difference (SMD), with an absolute standardized difference of greater than 10% taken to represent meaningful covariate imbalance. [9]. McNemar's test and paired t-test was used to assess the statistical significance of the risk difference for hospital outcomes and stratified log-rank was used to assess the statistical significance of the risk difference for mortality and MACCE at 5 years. Risk competing framework was used to estimate the treatment effect on MACCE individual components (survival R package and riskRegression R package). All p-values <0.05 were considered to indicate statistical significance.

Results

Study population

A total of 1525 patients were operated with intention to receive BITA grafting. Of those, 233 (15.3%) were converted to other conduit selection strategies. Incidence of conversion largely varied across 131 participating surgeons (Figure 1 and Supplementary Table 1). The most common reason for BITA grafts conversion was the evidence of at least one internal thoracic artery (ITA) not suitable which was reported in 77 (33.0%) cases. This was due to during harvesting (n=41), poor flow without apparent injury (n=23) and conduit too short for grafting (n=13). The second most common reasons for BITA conversion were poor target not suitable for BITA grafts in 44 cases (18.9%) and perceived increased risk for sternum complication (i.e. osteoporosis) in 38 cases (16.3%). Other causes were hemodynamic instability which occurred during BITA harvesting in 19 cases (8.1%), intraoperative evidence of other cardiac pathologies requiring intervention in 6 (2.6%) cases and time constrain in 6 (2.6%) cases. In 43 cases (18.5%), surgeons decided to not perform BITA grafts without providing a justification (Central Picture).

Baseline characteristics in the two groups are reported in Table 1. Overall subjects with intraoperative BITA graft conversion presented a higher risk profile. In particular they were

more likely to be older and female and were more likely to have diabetes, chronic obstructive pulmonary disease (COPD) and left ventricular ejection fraction (LVEF)<0.5. Intraoperative data breakdown according to causes of BITA conversion showed that increased body mass index (BMI) and diabetes was more common among those converted as perceived at higher risk for risk infection, female gender was more common among those with poor targets and reduced LVEF was more common among those with those with hemodynamic instability during ITA harvesting (Supplementary Table 3). After matching the two groups were comparable for all baseline risk factors (all SMD<0.10; Figure 2).

Intra-operative data

Intraoperative data are summarized in Table 2. Patients who had BITA graft conversion were more likely to be undergo on-pump surgery (23.2% vs. 42.1%) and to receive a lower number of grafts (2.95 ± 0.84 vs 3.21 ± 0.74), with LAD (95.3% vs 99.1%) and circumflex (82% vs 95.9%) territories being more likely to remain ungrafted. In the BITA conversion group, 19 (8.2%) patients received SVG only. Intraoperative data breakdown according to causes of BITA conversion showed that the number of grafts was lower among those found to have poor targets (2.52 ± 0.90), and the rate of patients receiving SVG only was higher among those with unsuitable ITA (18.2%) or hemodynamic instability during harvesting (15.8%) (Supplementary Table 4).

Outcomes

Hospital outcomes are summarised in Table 3. Overall patients requiring BITA graft conversion was not associated with a higher incidence of hospital morbidity or mortality. In particular, no patient requiring BITA graft conversion experienced hospital death and the need for intra-aortic balloon pump and need for repeat revascularization was comparable between the two groups. Hospital breakdown according to causes of BITA conversion showed that those requiring conversion for hemodynamic instability during ITA harvesting presented the highest

rate of IABP insertion, renal replacement therapy and postoperative MI (Supplementary Table 5).

Five-year outcomes are summarised in Table 4 and Figure 3. In patients requiring conversion we found a non-significant excess of deaths (11.9% vs 8.4%; $P=0.1$) and MACCE (17.1% vs 13.2%; $P=0.1$) mainly driven by an excess of revascularization (Figure 4). Those who required conversion for hemodynamic instability during ITA harvesting and found to have poor target or unsuitable ITA tended to have a higher rate of mortality and MACCE. (Supplementary Table 5).

Conduit selection in patients initially allocated to SITA

For descriptive purpose, we also reported conduits selection in those initially allocated to SITA graft. Among 1554 patients initially allocated to SITA, eight were not operated on (1 death, 4 withdrew, 3 cases with no reason reported) and the remaining 1546 underwent surgery. Of those, 1494 received SITA graft (96.7%) and 38 received BITA grafts (2.5%) for the following reasons: no other suitable conduit available ($n=21$, 1.4%), withdrew ($n=2$, 0.1%) and reason not report ($n=15$, 1.0%). Only 14 patients received neither SITA nor BITA (0.9%) for the following reasons: ITA unsuitable ($n=10$, 0.6%), unsuitable target ($n=2$, 0.1%), hemodynamic instability ($n=1$, 0.5%), need for unplanned surgery ($n=1$, 0.5%).

Discussion

Reasons beyond underutilization of the BITA graft remains uncertain [4,5]. Many surgeons just do not perform BITA grafts in view of the increased risk of sternal wound [10] and technical complexity [4]. However, the incidence of intraoperative BITA grafts conversion to other graft strategies in patients initially intended to receive BITA grafts remains unknown [7]. The perceived increased risk of operative morbidity related to intraoperative conversion can partially contribute to the reluctance of many surgeons to perform BITA grafts also in view of the current intense professional and public scrutiny of cardiac surgeons'.

236 The ART trial represents a unique opportunity to investigate the incidence and causes of
237 intraoperative BITA graft conversion [7]. Interestingly, despite participating surgeons were
238 anticipated to be expert in BITA grafts, the rate of intraoperative conversion was not irrelevant.
239 In fact 15.3% of patients initially intended to received BITA grafts required intraoperative
240 conversion to other conduit strategies. However, we noticed that there was a very large
241 variation in BITA grafting conversion across centres and surgeons which supports the central
242 role for individual surgeon experience. Interestingly, unsuitable ITA was reported as the main
243 reason (33%) for intraoperative BITA grafts conversion to other conduit strategies and it was
244 mainly related to injury during harvesting. Of notice, the rate of unsuitable ITA in those
245 allocated to SITA graft was only 0.6% suggesting that harvesting two ITAs is more demanding
246 and can influence surgeon's precisions. In addition, in 44 patients, BITA was not performed
247 because of poor target. Among those patients, only 7 patients required 1 grafts only. In all other
248 cases, SVG and/or RA were used in addition to SITA grafts, suggesting that technical difficulty
249 of performing BITA grafts rather than the absence of graftable targets. We also found that 19
250 patients become unstable during BITA harvesting and we can hypothesis that prolonged heart
251 compression secondary to the use of chest retractor during ITA harvesting may not be always
252 tolerated especially in presence of reduced LVEF. On the other hand, a main reason for
253 conversion not related to complication or technical complexity was the perception of increased
254 risk of sternal wound complication after chest opening (i.e. osteoporotic sternum). In case of
255 intraoperative conversion, SITA plus SVG was the most commonly opted strategy followed by
256 SITA plus RA. Of note, 19 patients (8.2%) received SVG only.

257 In contrast to other clinical scenarios when intraoperative conversion significantly increases
258 operative morbidity and mortality such as off-pump to on-pump conversion [11], BITA grafts
259 conversion was not associated with significantly higher rate of operative complications
260 although those requiring conversion for hemodynamic instability during ITA harvesting

presented a numerically higher rate of IABP insertion, renal replacement therapy and postoperative MI. At 5 years, we found a non-significant trend towards an excess of death and MACCE in patients requiring intraoperative conversion in particular among those with perioperative hemodynamic instability, poor target and unsuitable ITA. We can speculate that perioperative myocardial injury, lower number of grafts and excess of SVG only strategy in these three groups respectively might have partially contributed to this trend.

The unique technical challenges of BITA grafts fuels the perception that adoption of this myocardial revascularization strategy may increase operative morbidity in particular when intraoperative conversion to other conduit strategies is required. The present results support the hypothesis that BITA conversion does not significantly increase operative morbidity. However, the large variation in BITA conversion and its potential implication on late outcomes highlight the importance of negotiating the learning curve with appropriate patient selection, individualized grafting strategy, peer-to-peer training of the entire team, and graded clinical experience.

There are two main limitations in the present analysis. This is a retrospective analysis of the ART and we cannot exclude residual confounding factors between the two groups despite propensity score adjustment. The number of patients requiring conversion was relatively small and there was a relatively low incidence of adverse events. Therefore, the analysis was likely to be underpowered to detect significant difference between groups for comparisons. Finally, we had no information whether BITA injury during harvesting occurred with skeletonised or pedicled technique.

In conclusion, the incidence of intraoperative BITA graft conversion is not irrelevant also among experienced surgeons participating in ART. While intraoperative BITA grafts conversion does not increase the risk of operative mortality and major complications, BITA

285 conversion might be associated with poorer outcomes at long term follow-up. However, the
286 latter conclusions require further investigations.

287 **Appendix. Contributors:**

288 Ratnatunga C, Westaby S, Cook J, Wallis C, Wos S, Jasinski M, Widenka K, Blach A, Gocol
289 R, Hudziak D, Zurek P, Deja M, Bachowski R, Mrozek R, Kargul T, Domaradzki W,
290 Frackiewicz J, Zamvar V, Ezakadan D, Buxton B, Seevanayagam S, Matalanis G, Rosalion A,
291 Negri J, Moten S, Atkinson V, Newcomb A, Polidano P, Pana R, Gerbo S, O'Keefe P, von
292 Oppell U, Mehta D, Azzu A, Szafranek A, Kulatilake E, Evans J, Martin N, Banner D, Trivedi
293 U, Forsyth A, Hyde J, Cohen A, Lewis M, Gardner E, MacKenzie A, Cooter N, Joyce E, Parker
294 J, Champney F, Clark S, Dark J, Tocewicz K, Pillay T, Rowling S, Adams-Hall J, Bochenek
295 A, Cisowski M, Bolkowski M, Morawski W, Guc M, Krejca M, Wilczynski M, Duralek A,
296 Gerber W, Skarysz J, Shrestha R, Swiech W, Szmagala P, Krzych L, Pawlak A, Kepa K, Hasan
297 R, Keenan D, Prendergast B, Odom N, McLaughlin K, Cummings-Fosong G, Mathew C, Iles-
298 Smith H, Oomen A, Desai J, El-Gamel A, John L, Wendler O, Andrews M, Rance K, Williams
299 R, Hogervorst V, Gregory J, Jessup J, Knighton A, Hoare A, Ritchie A, Choong C, Nair S,
300 Jenkins D, Large S, Sudarshan C, Barman M, Dhital K, Routledge T, Rosengard B, Munday
301 H, Rintoul K, Jarrett E, Lao-Sirieix S, Wilkinson A, Garner L, Osmond J, Holcombe H, Cale
302 A, Griffin S, Dickson J, Spyt T, Hickey M, Sosnowski A, Peek G, Szostek J, Hadjinikalaou L,
303 Logtens E, Oakley M, Leji S, Gaer J, Amrani M, Dreyfus G, Bahrami T, de Robertis F, Baig
304 K, Asimakopoulos G, Vohra H, Pai V, Tadjkarimi S, Soleimani B, Stavri G, Bull G, Collappen
305 H, Sadowksi J, Gaweda B, Rudzinski P, Stolinski J, Konstanty-Kalandyk J, Moraes F, Moraes
306 C, Wanderley J, Pepper J, De Souza A, Petrou M, Trimlett R, Morgan T, Gavino J, Wang SF,
307 Chandrasekaran V, Kanagasaby R, Sarsam M, Ryan H, Billings L, Ruddick L, Achampong A,
308 Forster E, Pawlaczyk R, Siondalski P, Rogowski J, Roszak K, Jarmoszewicz K, Jagielak D,

309 Gafka S, Mannam G, Naguboyin G, Rao Sajja L, Dandu B, Briffa N, Braidley P, Cooper G,
310 Allen K, Sangha G, Bridge C, McMellon H, Casabona R, Actis Dato G, Bardi G, Del Ponte S,
311 Forsennati P, Parisi F, Punta G, Flocco R, Sansone F, Zingarelli E, Dihmis W, Kuduvali M,
312 Prince C, Rogers H, McQuade L, Anisimowicz L, Bokszański M, Pawliszak W, Kolakowski
313 J, Lau G, Ogorzeja W, Gumanska I, Kulinski P, Podesser B, Trescher K, Bernecker O,
314 Holzinger C, Binder K, Schor I, Bergmann P, Kassal H, Motovova B, Trehan N, Meharwal Z,
315 Malhotra R, Goel M, Kumer B, Bazaz S, Bake N, Singh A, Mishka Y, Gupta R, Basumatary
316 S, Zembala M, Szafron B, Pacholewicz J, Krason M, Farmas A, Wojarski J, Zych B, Szymanik
317 I, Kolwca M, Mazur W, Kurowicki A, Zurek S, Stacel T, Jaworska I, Sleight P, Channon K,
318 Farrell B, Stables R, Vermes G, Pearson J, Pitman M, Yusuf S, Pocock S, Julian D, Treasure
319 T, Von Oppel U, Kanagasabay R, Collinson J, Bakhai A, O'Hanlon R, Kotecha D, Qureshi K,
320 Geisler T, Manzano-Espinosa L.

References

1. Benedetto U, Montecalvo A, Kattach H, Amrani M, Raja SG; Harefield Cardiac Outcomes Research Group. Impact of the second internal thoracic artery on short- and long-term outcomes in obese patients: a propensity score matched analysis. *J Thorac Cardiovasc Surg.* 2015;149:841-7
2. Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary artery grafts on long-term survival: a meta-analysis approach. *Circulation.* 2014 Aug 12;130(7):539-45.
3. Head SJ, Börgermann J, Osnabrugge RL, Kieser TM, Falk V, Taggart DP, et al. Coronary artery bypass grafting: Part 2--optimizing outcomes and future prospects. *Eur Heart J.* 2013; 34:2873-86.
4. Catarino PA, Black E, Taggart DP. Why do UK cardiac surgeons not perform their first-choice operation for coronary artery bypass graft? *Heart.* 2002;88:643-4
5. Mastrobuoni S, Gawad N, Price J, Chan V, Ruel M, Mesana TG, et al. Use of bilateral internal thoracic artery during coronary artery bypass graft surgery in Canada: The bilateral internal thoracic artery survey. *J Thorac Cardiovasc Surg.* 2012; 144:874-9.
6. Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon K; ART Investigators. Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation [ISRCTN46552265]. *Trials.* 2006;7:7
7. Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, et al; ART Investigators. Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery Grafts. *N Engl J Med.* 2016;375:2540-9

- 344 8. D.B. Rubin. Multiple Imputation for Nonresponse in Surveys. J Wiley & Sons, New
345 York (1987)
- 346 9. Austin PC. A tutorial and case study in propensity score analysis: an application to
347 estimate the effect of in-hospital smoking cessation counseling on mortality.
348 Multivariate Behav Res, 2011;46:119–151.
- 349 10. Benedetto U, Altman DG, Gerry S, Gray A, Lees B, Pawlaczyk R, et al; Arterial
350 Revascularization Trial investigators. Pedicled and skeletonized single and bilateral
351 internal thoracic artery grafts and the incidence of sternal wound complications:
352 Insights from the Arterial Revascularization Trial. J Thorac Cardiovasc Surg. 2016
353 Jul;152(1):270-6.
- 354 11. Patel NC, Patel NU, Loulmet DF, McCabe JC, Subramanian VA. Emergency
355 conversion to cardiopulmonary bypass during attempted off-pump revascularization
356 results in increased morbidity and mortality. J Thorac Cardiovasc Surg. 2004
357 Nov;128(5):655-61.
- 358

359 Table 1. Baseline characteristics

	Requiring Conversion	Not Converted Before PSM	SMD before PSM	Not converted matched	SMD after PSM
N	233	1292		699	
Age (mean (sd))	65 (9)	63 (9)	0.229	65 (8)	0.019
Female = 1 (\%)	47 (20.2)	176 (13.6)	0.175	135 (19.3)	0.022
BMI (mean (sd))	29 (4)	28 (4)	0.117	29 (4)	0.005
SBP (mean (sd))	132 (18)	132 (18)	0.003	132 (18)	0.015
DBP (mean (sd))	75 (11)	75 (11)	0.011	75 (11)	0.016
Creatinine (mmol/L)	95 (21)	97 (21.5)	0.061	96 (21)	0.015
NYHA III/IV n(%)	42 (18.0)	290 (22.4)	0.110	131 (18.7)	0.018
Unstable angina n(%)	14 (6.0)	102 (7.9)	0.074	43 (6.2)	0.006
Treated Hypertension	177 (76.0)	1002 (77.6)	0.038	543 (77.7)	0.041
Treated Hyperlipaemia	222 (95.3)	1216 (94.1)	0.052	663 (94.8)	0.020
Diabetes n(%)			0.140		0.046
No	165 (70.8)	994 (76.9)		508 (72.7)	
On insulin	17 (7.3)	76 (5.9)		51 (7.3)	
Oral	51 (21.9)	222 (17.2)		140 (20.0)	
Smoking n(%)			0.046		0.032
Current	32 (13.7)	198 (15.3)		92 (13.2)	
Ex	129 (55.4)	696 (53.9)		381 (54.5)	
Never	72 (30.9)	398 (30.8)		226 (32.3)	
COPD n(%)	13 (5.6)	29 (2.2)	0.173	26 (3.7)	0.088
Asthma n(%)	11 (4.7)	67 (5.2)	0.021	32 (4.6)	0.007
PVD n(%)	17 (7.3)	85 (6.6)	0.028	49 (7.0)	0.011
TIA n(%)	8 (3.4)	42 (3.3)	0.010	19 (2.7)	0.041
CVA n(%)	5 (2.1)	37 (2.9)	0.046	12 (1.7)	0.031
MI n(%)	104 (44.6)	506 (39.2)	0.111	322 (46.1)	0.029
PCI n(%)	40 (17.2)	198 (15.3)	0.050	117 (16.7)	0.011
Preop AF pre n(%)	4 (1.7)	15 (1.2)	0.047	11 (1.6)	0.011
LVEF_pre (\%)			0.187		0.033
≥ 50% (good)	161 (69.1)	994 (76.9)		473 (67.7)	
31-49% (moderate)	67 (28.8)	268 (20.7)		209 (29.9)	
≤ 30% (poor)	5 (2.1)	30 (2.3)		17 (2.4)	
LMD n(%)	40 (17.2)	282 (21.8)	0.118	127 (18.2)	0.026

360 SMD: standardized mean difference; PSM: propensity score matching; BMI: body mass index;
361 SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive
362 pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA:
363 cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous coronary intervention;
364 AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease.

365

	Requiring Conversion	Not Converted Before PSM	P-value Before PSM	Not converted matched	P-value After PSM
n	233	1292		699	
Off-pump n(%)	54 (23.2)	584 (45.2)	<0.001	294 (42.1)	<0.001
LAD n(%)	222 (95.3)	1278 (98.9)	<0.001	693 (99.1)	<0.001
Circumflex n(%)	191 (82.0)	1231 (95.3)	<0.001	670 (95.9)	<0.001
RCA n(%)	157 (67.4)	890 (68.9)	0.705	488 (69.8)	0.539
Diagonal branches n(%)	64 (27.5)	395 (30.6)	0.382	206 (29.5)	0.617
N grafts (mean (sd))	2.95 (0.84)	3.21 (0.77)	<0.001	3.21 (0.74)	<0.001
Conduits (%)			<0.001		<0.001
Unknown	0 (0.0)	2 (0.2)		0 (0.0)	
BITA		270 (20.9)		139 (19.9)	
BITA+RA		215 (16.6)		115 (16.5)	
BITA+RA+SV		44 (3.4)		23 (3.3)	
BITA+SV		761 (58.9)		422 (60.4)	
LITA	7 (3.0)				
LITA+RA	22 (9.4)				
LITA+RA+SV	12 (5.2)				
LITA+SV	156 (67.0)				
RA	1 (0.4)				
RA+SV	2 (0.9)				
RITA	3 (1.3)				
RITA+RA	2 (0.9)				
RITA+RA+SV	1 (0.4)				
RITA+SV	8 (3.4)				
SVG	19 (8.2)				

367 PSM: propensity score matching; LAD: left anterior descending artery; RCA: right coronary
368 artery; BITA; bilateral internal thoracic arteries; RA: radial artery; SVG: saphenous vein graft

369 Table 3. Hospital outcomes

	Requiring Conversion	Not Converted Before PSM	P-value Before PSM	Not converted matched	P-value After PSM
N	233	1292		699	
Re-exploration for bleeding n(%)	10 (4.3)	47 (3.6)	0.8	20 (2.9)	0.4
IABP insertion n(%)	12 (5.2)	55 (4.3)	0.7	36 (5.2)	1
Renal replacement therapy n(%)	6 (2.6)	85 (6.6)	0.03	52 (7.4)	0.01
Sternal complications n(%)	13 (5.6)	64 (5.0)	0.8	36 (5.2)	0.9
Death n(%)	0 (0.0)	17 (1.3)	0.2	11 (1.6)	0.1
MI n(%)	7 (3.0)	18 (1.4)	0.1	12 (1.7)	0.4
CVA n(%)	5 (2.1)	13 (1.0)	0.2	9 (1.3)	0.5
Revascularization n(%)	1 (0.4)	9 (0.7)	1	5 (0.7)	1
POAF n(%)	69 (29.6)	329 (25.5)	0.2	208 (29.8)	1

370 PSM: propensity score matching; IABP: intra-aortic balloon pump; Myocardial infarction;

371 CVA: cerebrovascular accident; POAF: postoperative atrial fibrillation

372 Table 4. Five-year outcomes

	Converted	Not Converted Before PSM	P-value Before PSM	Not converted matched	P-value
N	233	1292		699	
Mortality at 5 years	27(11.9)	104(8.2)	0.08	58(8.4)	0.1
MACCE at 5 years	39(17.1)	155(12.4)	0.03	90(13.2)	0.1
cardiovascular death	8(3.5)	44(3.5)	1	29(4.2)	0.7
MI	9(3.9)	42(3.3)	0.6	24(3.5)	0.7
CVA	7(3.0)	31(2.4)	0.6	19(2.7)	0.8
Revascularization	12(8.2)	81(6.4)	0.2	43(6.2)	0.2

373 PSM: propensity score matching; MACCE: major adverse cardiac and cerebrovascular events;

374 MI: myocardial infarction; CVA: cerebrovascular accident

375

376 Figure Legend

377 Central Picture: BITA grafts allocation and conversion in the ART (BITA: bilateral interval
378 thoracic artery; SITA: single internal thoracic artery; ITA: internal thoracic artery)

379 Figure 1. Scatter plot showing total number of cases initially allocated to BITA grafts
380 performed by individual surgeons and relative rate of BITA conversion.

381 Figure 2. Changes in standardized mean after matching (SMD: standardized mean difference;
382 PSM: propensity score matching; BMI: body mass index; SBP: systolic blood pressure; DBP:
383 diastolic blood pressure; COPD: chronic obstructive pulmonary disease; PVD: peripheral
384 vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; MI:
385 myocardial infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation;
386 LVEF: left ventricular ejection fraction; LMD: left main disease).

387 Figure 3. Cumulative incidence of mortality and major adverse cardiac and cerebrovascular
388 events (MACCE) in the matched sample

389 Figure 4. Cumulative incidence of cardiovascular (CV) death, myocardial infarction (MI),
390 cerebrovascular accident (CVA) and revascularization in the matched sample

391 Video. Skeletonised left internal thoracic artery during off-pump surgery

392 Supplementary Table 1. Number of cases performed initially allocated to bilateral interval
393 thoracic artery (BITA) grafts and BITA conversion rate.

#Surgeon	Total number of cases performed initially allocated to BITA grafts	%BITA grafts conversion
Unknow	67	23.9%
1	1	0.0%
2	1	100.0%
3	1	0.0%
4	1	0.0%
5	1	100.0%
6	15	0.0%
7	9	22.2%
8	6	0.0%
9	1	100.0%
10	9	33.3%
11	1	0.0%
12	1	100.0%
13	2	100.0%
14	1	0.0%
15	1	0.0%
16	15	6.7%
17	5	0.0%
18	8	0.0%
19	18	5.6%
20	17	5.9%
21	15	13.3%
22	6	33.3%
23	20	20.0%
24	9	11.1%
25	15	0.0%
26	7	28.6%
27	30	30.0%
28	5	0.0%
29	6	0.0%
30	8	50.0%
31	4	0.0%
32	9	0.0%
33	15	13.3%

34	7	0.0%
35	40	10.0%
36	1	0.0%
37	4	25.0%
38	10	50.0%
39	13	23.1%
40	7	28.6%
41	1	0.0%
42	2	0.0%
43	12	16.7%
44	1	0.0%
45	12	41.7%
46	2	0.0%
47	2	0.0%
48	1	0.0%
49	34	20.6%
50	9	55.6%
51	24	8.3%
52	15	26.7%
53	17	70.6%
54	1	0.0%
55	5	0.0%
56	1	0.0%
57	29	20.7%
58	8	25.0%
59	1	0.0%
60	4	25.0%
61	7	42.9%
62	3	0.0%
63	1	0.0%
64	5	0.0%
65	8	37.5%
66	12	16.7%
67	2	50.0%
68	17	23.5%
69	28	3.6%
70	14	21.4%
71	1	100.0%
72	4	0.0%
73	2	0.0%
74	29	10.3%

75	41	0.0%
76	18	38.9%
77	22	31.8%
78	4	25.0%
79	3	100.0%
80	1	0.0%
81	33	6.1%
82	4	0.0%
83	1	0.0%
84	9	0.0%
85	1	0.0%
86	16	0.0%
87	1	0.0%
88	1	0.0%
89	2	50.0%
90	16	6.3%
91	11	54.5%
92	19	21.1%
93	3	33.3%
94	19	42.1%
95	1	100.0%
96	4	0.0%
97	1	100.0%
98	1	0.0%
99	18	5.6%
100	22	13.6%
101	2	0.0%
102	2	0.0%
103	8	0.0%
104	33	0.0%
105	1	0.0%
106	12	16.7%
107	12	8.3%
108	3	0.0%
109	4	100.0%
110	1	0.0%
111	2	100.0%
112	22	18.2%
113	4	0.0%
114	10	10.0%
115	2	0.0%

116	2	0.0%
117	1	0.0%
118	211	1.9%
119	1	0.0%
120	16	25.0%
121	1	0.0%
122	15	33.3%
123	8	0.0%
124	3	0.0%
125	1	100.0%
126	11	9.1%
127	3	0.0%
128	1	0.0%
129	33	15.2%
130	99	13.1%
131	3	33.3%

Supplementary Table 2. Baseline characteristics according to cause of bilateral interval thoracic artery (BITA) grafts conversion

	High risk for sternal complication	At least 1 ITA not suitable	Target not suitable	Other cardiac pathologies	Justification not provided	Time constrain	Unstable during ITA harvesting
N	38	77	44	6	43	6	19
Age (mean (sd))	65.01 (8.87)	65.59 (8.19)	65.64 (9.39)	68.88 (8.63)	64.43 (8.63)	64.44 (8.29)	65.76 (8.68)
Female n(%)	7 (18.4)	16 (20.8)	12 (27.3)	0 (0.0)	10 (23.3)	0 (0.0)	2 (10.5)
BMI (mean (sd))	30.21 (4.28)	27.51 (3.25)	28.82 (3.11)	27.91 (2.60)	29.53 (4.01)	29.10 (2.85)	28.54 (4.61)
SBP (mean (sd))	132 (15)	131 (20)	134 (19)	129 (15)	130 (16)	140 (12)	131 (17)
DBP (mean (sd))	78 (10)	74 (10)	75 (10)	81 (11)	74 (13)	80 (15)	74 (10)
Creatinine (mmol/L)	97.49 (23.50)	94.27 (18.31)	99.48 (25.05)	100.08 (25.67)	92.51 (18.37)	89.00 (11.47)	93.85 (20.55)
NYHA III/IV n(%)	4 (10.5)	17 (22.1)	6 (13.6)	2 (33.3)	8 (18.6)	2 (33.3)	3 (15.8)
Unstable angina n(%)	1 (2.6)	6 (7.8)	3 (6.8)	1 (16.7)	1 (2.3)	0 (0.0)	2 (10.5)
Treated Hypertension	29 (76.3)	53 (68.8)	33 (75.0)	6 (100.0)	32 (74.4)	6 (100.0)	18 (94.7)
Treated Hyperlipaemia	38 (100.0)	73 (94.8)	42 (95.5)	6 (100.0)	39 (90.7)	6 (100.0)	18 (94.7)
Diabetes n(%)							
No	24 (63.2)	56 (72.7)	30 (68.2)	4 (66.7)	29 (67.4)	4 (66.7)	18 (94.7)
On insulin	3 (7.9)	9 (11.7)	2 (4.5)	0 (0.0)	3 (7.0)	0 (0.0)	0 (0.0)
Oral	11 (28.9)	12 (15.6)	12 (27.3)	2 (33.3)	11 (25.6)	2 (33.3)	1 (5.3)
Smoking n(%)							
Current	6 (15.8)	7 (9.1)	7 (15.9)	1 (16.7)	7 (16.3)	1 (16.7)	3 (15.8)
Ex	18 (47.4)	46 (59.7)	24 (54.5)	2 (33.3)	22 (51.2)	4 (66.7)	13 (68.4)
Never	14 (36.8)	24 (31.2)	13 (29.5)	3 (50.0)	14 (32.6)	1 (16.7)	3 (15.8)
COPD n(%)	3 (7.9)	4 (5.2)	1 (2.3)	0 (0.0)	4 (9.3)	0 (0.0)	1 (5.3)
Asthma n(%)	3 (7.9)	1 (1.3)	0 (0.0)	1 (16.7)	6 (14.0)	0 (0.0)	0 (0.0)
PVD n(%)	4 (10.5)	5 (6.5)	1 (2.3)	1 (16.7)	4 (9.3)	0 (0.0)	2 (10.5)

TIA n(%)	2 (5.3)	3 (3.9)	3 (6.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
CVA n(%)	1 (2.6)	1 (1.3)	1 (2.3)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.3)
MI n(%)	13 (34.2)	38 (49.4)	21 (47.7)	2 (33.3)	21 (48.8)	2 (33.3)	7 (36.8)
PCI n(%)	14 (36.8)	10 (13.0)	9 (20.5)	1 (16.7)	2 (4.7)	0 (0.0)	4 (21.1)
Preop AF pre n(%)	2 (5.3)	1 (1.3)	0 (0.0)	0 (0.0)	1 (2.3)	0 (0.0)	0 (0.0)
LVEF_pre (\%)							
≥ 50% (good)	31 (81.6)	52 (67.5)	30 (68.2)	3 (50.0)	31 (72.1)	4 (66.7)	10 (52.6)
31-49% (moderate)	6 (15.8)	24 (31.2)	12 (27.3)	3 (50.0)	12 (27.9)	2 (33.3)	8 (42.1)
≤ 30% (poor)	1 (2.6)	1 (1.3)	2 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
LMD n(%)	7 (18.4)	14 (18.2)	7 (15.9)	1 (16.7)	5 (11.6)	3 (50.0)	3 (15.8)

ITA: internal thoracic artery; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; TIA: transient ischemic attack; CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous coronary intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; LMD: left main disease.

Supplementary Table 3. Operative data according to cause of bilateral interval thoracic artery (BITA) grafts conversion.

	High risk for sternal complication	At least 1 ITA not suitable	Target not suitable	Other cardiac pathologies	Justification not provided	Time constrain	Unstable during ITA harvesting
n	38	77	44	6	43	6	19
Off-pump n(%)	4 (10.5)	23 (29.9)	15 (34.1)	1 (16.7)	9 (20.9)	0 (0.0)	2 (10.5)
LAD n(%)	37 (97.4)	76 (98.7)	37 (84.1)	5 (83.3)	43 (100.0)	6 (100.0)	18 (94.7)
Circumflex n(%)	37 (97.4)	70 (90.9)	25 (56.8)	5 (83.3)	33 (76.7)	6 (100.0)	15 (78.9)
RCA n(%)	24 (63.2)	52 (67.5)	31 (70.5)	3 (50.0)	26 (60.5)	6 (100.0)	15 (78.9)
Diagonal branches n(%)	12 (31.6)	22 (28.6)	7 (15.9)	1 (16.7)	14 (32.6)	2 (33.3)	6 (31.6)
N grafts (mean (sd))	3.03 (0.79)	3.04 (0.77)	2.52 (0.90)	2.83 (1.47)	3.00 (0.82)	3.50 (0.55)	3.16 (0.76)
Conduits (%)							
LITA	0 (0.0)	0 (0.0)	4 (9.1)	1 (16.7)	2 (4.7)	0 (0.0)	0 (0.0)
LITA+RA	2 (5.3)	3 (3.9)	4 (9.1)	0 (0.0)	13 (30.2)	0 (0.0)	0 (0.0)
LITA+RA+SV	5 (13.2)	1 (1.3)	1 (2.3)	0 (0.0)	4 (9.3)	0 (0.0)	1 (5.3)
LITA+SV	30 (78.9)	48 (62.3)	32 (72.7)	5 (83.3)	21 (48.8)	5 (83.3)	15 (78.9)
RA	0 (0.0)	0 (0.0)	1 (2.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
RA+SV	0 (0.0)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
RITA	0 (0.0)	1 (1.3)	2 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
RITA+RA	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	1 (2.3)	0 (0.0)	0 (0.0)
RITA+RA+SV	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
RITA+SV	0 (0.0)	6 (7.8)	0 (0.0)	0 (0.0)	1 (2.3)	1 (16.7)	0 (0.0)
SVG	1 (2.6)	14 (18.2)	0 (0.0)	0 (0.0)	1 (2.3)	0 (0.0)	3 (15.8)

ITA: internal thoracic artery; LAD: left anterior descending artery; RCA: right coronary artery; BITA; bilateral internal thoracic arteries; RA: radial artery; SVG: saphenous vein graft

Supplementary Table 4. Hospital outcomes and 5-year mortality and major adverse cardiac and cerebrovascular events (MACCE) according to cause of bilateral interval thoracic artery (BITA) grafts conversion

	High risk for sternal complication	ITA not suitable	Target not suitable	Other cardiac pathologies	Justification not provided	Time constrain	Unstable during harvesting
N	38	77	44	6	43	6	19
Re-exploration for bleeding n(%)	0 (0.0)	2 (2.6)	2 (4.5)	0 (0.0)	6 (14.0)	0 (0.0)	0 (0.0)
IABP insertion n(%)	3 (7.9)	3 (3.9)	1 (2.3)	0 (0.0)	0 (0.0)	0 (0.0)	5 (26.3)
Renal replacement therapy n(%)	1 (2.6)	1 (1.3)	1 (2.3)	0 (0.0)	1 (2.3)	1 (16.7)	1 (5.3)
Sternal complications n(%)	3 (7.9)	2 (2.6)	2 (4.5)	1 (16.7)	4 (9.3)	0 (0.0)	1 (5.3)
Death n(%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
MI n(%)	0 (0.0)	4 (5.2)	1 (2.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.5)
CVA n(%)	1 (2.6)	3 (3.9)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)
Revascularization n(%)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
POAF n(%)	12 (31.6)	21 (27.3)	13 (29.5)	4 (66.7)	10 (23.3)	2 (33.3)	7 (36.8)
Mortality at 5 years	4 (10.5)	9(11.9)	6(13.8)	0(0)	6(14.1)	0(0)	2(10.8)
MACCE at 5 years	3(8)	18(24)	8(18.3)	1(16.7)	4(9.7)	1(16.7)	4(21.1)

ITA: internal thoracic artery; IABP: intra-aortic balloon pump; Myocardial infarction; CVA: cerebrovascular accident; POAF: postoperative atrial fibrillation; MACCE: major adverse cardiac and cerebrovascular events